BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

NCT03638180 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Cough

Interventions

DRUG: BLU-5937
DRUG: Placebo

Sponsor

Bellus Health Inc. - a GSK company